11 completed. 11 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 11 |
| Phase 3 | 2 | Completed 2 |
Follow Intestinal Polyposis: new trials by email Literature Review of Intestinal Polyposis trials Research Report on Intestinal Polyposis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The CHAMP-study: The CHemopreventive Effect of Lithium in Familial AdenoMatous Polyposis Lithium Carbonate - Familial Adenomatous Polyposis | Phase 2 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 12 | 2022-06-02 | 2024-10-04 |
| Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance Encapsulated Rapamycin (eRapa) - Familial Adenomatous Polyposis | Phase 2 | Completed | Rapamycin Holdings Inc. | 30 | 2021-01-18 | 2026-10-22 |
| Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer Erlotinib, Erlotinib Hydrochloride - Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis | Phase 2 | Completed | National Cancer Institute (NCI) | 46 | 2017-10-27 | 2022-07-26 |
| Sirolimus and Familial Adenomatous Polyposis (FAP) Sirolimus - Adenomatous Polyposis Coli | Phase 2 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 4 | 2017-10-03 | 2024-10-24 |
| The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study Metformin, Placebo - Familial Adenomatous Polyposis | Phase 2 | Completed | Yonsei University | 34 | 2013-02-15 | 2021-09-20 |
| Curcumin in Treating Patients With Familial Adenomatous Polyposis Curcumin, Laboratory Biomarker Analysis, Placebo - Familial Adenomatous Polyposis | Phase 2 | Completed | National Cancer Institute (NCI) | 44 | 2010-10-01 | 2017-09-29 |
| A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients Erlotinib, Sulindac, Placebo A - Adenomatous Polyposis Coli | Phase 2 | Completed | University of Utah | 92 | 2010-04-01 | 2016-06-17 |
| Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Celecoxib, Ursodeoxycholic acid, Placebo - Familial Adenomatous Polyposis, Duodenal Neoplasms | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 37 | 2009-05-01 | 2013-05-16 |
| Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA Eicosapentanoic Acid (EPA), Endoscopy, Biopsies taken - Familial Adenomatous Polyposis Coli, FAP | Phase 2 / Phase 3 | Completed | S.L.A. Pharma AG | 58 | 2006-11-01 | 2014-08-22 |
| Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers Celecoxib, Colonoscopy Biopsy - Familial Adenomatous Polyposis | Phase 2 | Completed | M.D. Anderson Cancer Center | 51 | 2003-08-20 | 2023-02-13 |
| Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis Celecoxib, Placebo, eflornithine - Colorectal Cancer, Familial Adenomatous Polyposis | Phase 2 | Completed | National Cancer Institute (NCI) | 205 | 2001-12-13 | 2020-09-29 |
Adenomatous Polyposis Coli (11) · Colorectal Neoplasms (2) · Polyps (2) · Adenoma (1) · Adenomatous Polyps (1) · Attenuated familial adenomatous polyposis (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Duodenal Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Genetic Diseases, Inborn (1) · Hyperplasia (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1)
Colonic Diseases (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Neoplasms by Site (11) · Neoplasms, Glandular and Epithelial (11) · Adenoma (10) · Adenomatous Polyps (10) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Gastrointestinal Diseases (10) · Gastrointestinal Neoplasms (10) · Genetic Diseases, Inborn (10) · Intestinal Diseases (10)
Celecoxib (3) · Erlotinib Hydrochloride (2) · Curcumin (1) · Eflornithine (1) · Eicosapentaenoic Acid (1) · Endoscopy (1) · Lithium Carbonate (1) · Metformin (1) · Sirolimus (1) · Sulindac (1) · Surveys and Questionnaires (1) · Ursodeoxycholic Acid (1)
National Cancer Institute (NCI) (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · M.D. Anderson Cancer Center (1) · Radboud University Medical Center (1) · Rapamycin Holdings Inc. (1) · S.L.A. Pharma AG (1) · University of Utah (1) · Yonsei University (1)
United States (6) · Netherlands (3) · Puerto Rico (2) · South Korea (1) · United Kingdom (1)
Bjorn WH van Heumen, MD (1) · Ellen Kampman, Ph D (1) · Evelien Dekker, MD, PhD (1) · Fokko M Nagengast, MD, Ph D (1) · Francis Giardiello (1) · Gary Shangold, MD (1) · Imad Shureiqi, MD (1) · Nicholas J West, MB BS FRCS (1) · Niloy J Samadder (1) · Niloy J Samadder, MD (1) · Patrick Lynch (1) · Patrick Lynch, MD, JD (1) · Randall Burt, MD (1) · Robert S. Bresalier, MD (1) · Wilbert HM Peters, Ph D (1)
PMID 37119510, PMID 20348368, PMID 23919274, PMID 24245549, PMID 25792707, PMID 27002448, PMID 29423501, PMID 29802852, PMID 30012100, PMID 33376109, PMID 33509804, PMID 35636921, PMID 35962368
N01CN00042 (1), P01CA073992 (1), P30CA006973 (1), P30CA015083 (1), P30CA016672 (1), R01CA106577 (1), R01CA134620 (1)